Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Jun;4(12):243.
doi: 10.21037/atm.2016.05.45.

Is the regulation of SIRT1 by miRNA-34a the key to mesenchymal stem cell survival?

Michael A Bellio  1 , Wayne Balkan  1 , Joshua M Hare  1 , Ivonne Hernandez Schulman  2
Affiliations
Comment

Is the regulation of SIRT1 by miRNA-34a the key to mesenchymal stem cell survival?

Michael A Bellio et al. Ann Transl Med. 2016 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Dr. Hare has a patent for cardiac cell-based therapy; he holds equity in Vestion Inc., maintains a professional relationship with Vestion as a consultant and member of the Board of Directors and Scientific Advisory Board, and is a shareholder in Longeveron LLC. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Sanina C, Hare JM. Mesenchymal stem cells as a biological drug for heart disease: where are we with cardiac cell-based therapy? Circ Res 2015;117:229-33. 10.1161/CIRCRESAHA.117.306306 - DOI - PMC - PubMed
    1. Karantalis V, Hare JM. Use of mesenchymal stem cells for therapy of cardiac disease. Circ Res 2015;116:1413-30. 10.1161/CIRCRESAHA.116.303614 - DOI - PMC - PubMed
    1. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 2012;308:2369-79. 10.1001/jama.2012.25321 - DOI - PMC - PubMed
    1. Premer C, Blum A, Bellio MA, et al. Allogeneic mesenchymal stem cells restore endothelial function in heart failure by stimulating endothelial progenitor cells. EBioMedicine 2015;2:467-75. 10.1016/j.ebiom.2015.03.020 - DOI - PMC - PubMed
    1. Kanashiro-Takeuchi RM, Schulman IH, Hare JM. Pharmacologic and genetic strategies to enhance cell therapy for cardiac regeneration. J Mol Cell Cardiol 2011;51:619-25. 10.1016/j.yjmcc.2011.05.015 - DOI - PMC - PubMed

LinkOut - more resources